Insider at

04

Insider transactions

05
0 buys (P) 0 sells (S) Net: $0 + 6 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Aug. 15, 2024 INNV F 14,303 $6.22 $88,965 220,908 Direct -6.08% Disposed 44.7% (price as of 2026-10-05)
June 6, 2024 INNV F 8,023 $4.83 $38,751 235,211 Direct -3.30% Disposed 86.3% (price as of 2026-10-05)
June 4, 2024 INNV A 108,226 · · 243,234 Direct +80.16% Acquired (price as of 2026-10-05)
Aug. 15, 2023 INNV F 9,737 $5.60 $54,527 135,008 Direct -6.73% Disposed 60.7% (price as of 2026-10-05)
June 6, 2023 INNV A 52,152 · · 144,745 Direct +56.32% Acquired (price as of 2026-10-05)
Aug. 15, 2022 INNV A 92,593 · · 92,593 Direct · Acquired (price as of 2026-10-05)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

INNV

Chief Medical Officer(6)
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2023 $351,667 · $800,008 · $183,014 · $4,000 $1,338,689

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.